ID

37352

Descripción

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02514850

Link

https://clinicaltrials.gov/show/NCT02514850

Palabras clave

Versiones (1)
  1. 20/7/19 20/7/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

20 de julio de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes Mellitus NCT02514850

Inglés

Eligibility Type 2 Diabetes Mellitus NCT02514850

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
Descripción

Non-Insulin-Dependent Diabetes Mellitus Disease length

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
hba1c levels ≤ 9.0%
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
total insulin dose of < 1.2 u/kg/day
Descripción

Insulin Total Daily Dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C2348070
body mass index between 20.0 and 35.0 kg/m2 (both inclusive)
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
body weight ≤ 125.0 kg
Descripción

Body Weight

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005910
fasting serum c-peptide ≤ 1 nmol/l
Descripción

Fasting C-peptide level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2208720
treated with a stable insulin regimen for ≥ 3 months prior to screening
Descripción

Insulin regime Stable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0557978
UMLS CUI [1,2]
C0205360
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes mellitus
Descripción

Diabetes Mellitus, Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011854
known or suspected allergy to the trial products or related products
Descripción

Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Pharmaceutical Products Related | Hypersensitivity Suspected Pharmaceutical Products Related

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0013230
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0013227
UMLS CUI [3,3]
C0439849
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0013227
UMLS CUI [4,4]
C0439849
previous participation in this trial. participation is defined as randomised
Descripción

Study Subject Participation Status | Randomization

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0034656
participation in any clinical trial within 3 months prior to this trial
Descripción

Study Subject Participation Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the investigator considering the underlying disease
Descripción

Haematology test abnormal considering Primary disorder | Abnormal biochemistry finding considering Primary disorder | Lipids abnormal considering Primary disorder | Urine screening abnormal considering Primary disorder

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1112712
UMLS CUI [1,2]
C0750591
UMLS CUI [1,3]
C0277554
UMLS CUI [2,1]
C0586680
UMLS CUI [2,2]
C0750591
UMLS CUI [2,3]
C0277554
UMLS CUI [3,1]
C0549634
UMLS CUI [3,2]
C0750591
UMLS CUI [3,3]
C0277554
UMLS CUI [4,1]
C0438142
UMLS CUI [4,2]
C0750591
UMLS CUI [4,3]
C0277554
supine blood pressure at screening outside the range of 90-160 mmhg for systolic or 50-95 mmhg for diastolic and/or resting supine heart rate outside the range 50 -90 beats per minute. this exclusion criterion also pertains to subjects being on antihypertensives
Descripción

Lying systolic blood pressure | Lying diastolic blood pressure | Heart rate supine resting | Antihypertensive Agents

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1319895
UMLS CUI [2]
C1319896
UMLS CUI [3,1]
C3262833
UMLS CUI [3,2]
C0035253
UMLS CUI [4]
C0003364
use of glp-1 receptor agonists or oral antidiabetic drugs (oads) other than stable intake of metformin within 4 weeks prior to screening
Descripción

GLP-1 Receptor Agonist | Antidiabetics Oral | Exception Metformin Intake Stable

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2917359
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025598
UMLS CUI [3,3]
C1512806
UMLS CUI [3,4]
C0205360
women of child bearing potential, not willing to use contraceptive methods
Descripción

Childbearing Potential Contraceptive methods Unwilling

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes Mellitus NCT02514850

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hemoglobin A1c measurement
Item
hba1c levels ≤ 9.0%
boolean
C0474680 (UMLS CUI [1])
Insulin Total Daily Dose
Item
total insulin dose of < 1.2 u/kg/day
boolean
C0021641 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
Body mass index
Item
body mass index between 20.0 and 35.0 kg/m2 (both inclusive)
boolean
C1305855 (UMLS CUI [1])
Body Weight
Item
body weight ≤ 125.0 kg
boolean
C0005910 (UMLS CUI [1])
Fasting C-peptide level
Item
fasting serum c-peptide ≤ 1 nmol/l
boolean
C2208720 (UMLS CUI [1])
Insulin regime Stable
Item
treated with a stable insulin regimen for ≥ 3 months prior to screening
boolean
C0557978 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes mellitus
boolean
C0011854 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Pharmaceutical Products Related | Hypersensitivity Suspected Pharmaceutical Products Related
Item
known or suspected allergy to the trial products or related products
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0013227 (UMLS CUI [4,3])
C0439849 (UMLS CUI [4,4])
Study Subject Participation Status | Randomization
Item
previous participation in this trial. participation is defined as randomised
boolean
C2348568 (UMLS CUI [1])
C0034656 (UMLS CUI [2])
Study Subject Participation Status
Item
participation in any clinical trial within 3 months prior to this trial
boolean
C2348568 (UMLS CUI [1])
Haematology test abnormal considering Primary disorder | Abnormal biochemistry finding considering Primary disorder | Lipids abnormal considering Primary disorder | Urine screening abnormal considering Primary disorder
Item
clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the investigator considering the underlying disease
boolean
C1112712 (UMLS CUI [1,1])
C0750591 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0586680 (UMLS CUI [2,1])
C0750591 (UMLS CUI [2,2])
C0277554 (UMLS CUI [2,3])
C0549634 (UMLS CUI [3,1])
C0750591 (UMLS CUI [3,2])
C0277554 (UMLS CUI [3,3])
C0438142 (UMLS CUI [4,1])
C0750591 (UMLS CUI [4,2])
C0277554 (UMLS CUI [4,3])
Lying systolic blood pressure | Lying diastolic blood pressure | Heart rate supine resting | Antihypertensive Agents
Item
supine blood pressure at screening outside the range of 90-160 mmhg for systolic or 50-95 mmhg for diastolic and/or resting supine heart rate outside the range 50 -90 beats per minute. this exclusion criterion also pertains to subjects being on antihypertensives
boolean
C1319895 (UMLS CUI [1])
C1319896 (UMLS CUI [2])
C3262833 (UMLS CUI [3,1])
C0035253 (UMLS CUI [3,2])
C0003364 (UMLS CUI [4])
GLP-1 Receptor Agonist | Antidiabetics Oral | Exception Metformin Intake Stable
Item
use of glp-1 receptor agonists or oral antidiabetic drugs (oads) other than stable intake of metformin within 4 weeks prior to screening
boolean
C2917359 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C1512806 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
Childbearing Potential Contraceptive methods Unwilling
Item
women of child bearing potential, not willing to use contraceptive methods
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial